Print Friendly, PDF & Email

NCT/Study#

NCT03229200 /

PCYC-1145-LT

Extended Treatment Protocol For Subjects Continuing To Benefit From Ibrutinib After Completion Of Ibrutinib Clinical Trials

DISEASE GROUP:
Lymphoma
current phase:
NA
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: